Shots:

• The submission is based on SUSTAIN FORTE trial assessing Ozempic (2.0mg- qw) vs Ozempic (1.0mg) in 961 people with T2D in need of treatment intensification
• Result: 2.0 mg of dose achieved significant and superior reduction in HbA1c @40wks.- both the doses are safe and well-tolerated
• Ozempic is a glucagon-like peptide-1 (GLP-1) analogue and is currently approved in the EU for 0.5 mg and 1.0 mg doses to treat T2D in adults

­ Ref: GlobeNewswire | Image: Facebook